In case you missed them, here are some news stories that appeared in MS News Today that caught my eye over the past week.
At first glance, the headlines about this drug announced what seemed to be an MS patient’s dream: a safe, simple and inexpensive drug that can reduce disease progression in some people. But read editorial. I’ll be writing about this in detail in my June 6 column of The MS Wire.‘s story carefully. The study was very small and there are other things that take some of the luster off of this announcement. There were enough items that the New England Journal of Medicine felt the need to write them in an
A common acne medicine called minocycline can reduce the rate of multiple sclerosis progression in patients who are at early stages of the disease, according to a Phase 3 clinical trial.
The finding was from the MinoCIS trial (NCT00666887) of minocycline, which goes by the brand name Mynocan and other labels. Canadian researchers published the study, “Trial of Minocycline in a Clinically Isolated Syndrome of Multiple Sclerosis,” in the New England Journal of Medicine.
An injectable gel that could treat RRMS symptoms not touched by heavy-duty steroids sounds interesting to me. So, this study seems to be one to watch. But this drug has been around for over four decades and it comes with a very high price tag. (Be sure to read to the end of story to see how much the price has jumped over those years). So, the thing to watch will really be whether Acthar Gel’s reward is worth its very significant cost.
Mallinckrodt has enrolled its first relapsing multiple sclerosis (MS) patient into a Phase 4 clinical trial (NCT03126760) with H.P. Acthar Gel (repository corticotropin injection) to see if the therapy can help treat relapse symptoms in patients who did not respond to high-dose steroids.
If successful, the trial might resolve at least part of the controversy over the high price of the gel, which has been on the market since the 1970s.
The study, called OPTIONS, will enroll patients with an ongoing relapse who have been treated with a high-dose corticosteroid. Patients will be randomized to receive either Acthar Gel or a placebo. After the treatment, researchers will measure changes in disability levels using the Expanded Disability Status Scale (EDSS).
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?